Home > News > Starpharma Phase 1 Preliminary Report
November 18th, 2004
Starpharma Phase 1 Preliminary Report
Abstract:
Starpharma Holdings Limited today announced that VivaGel™, its vaginal microbicidal gel for the prevention of HIV was found to be well tolerated during a clinical trial held in Australia.
VivaGel™ is the first drug product in the world based upon nanoscale dendrimers to enter human trials.
Source:
pharmalive
Bookmark:
Possible Futures
Lifeboat publishes its first book: The Lifeboat Foundation has published its first book, "The Human Race to the Future: What Could Happen -- and What to Do" May 14th, 2013
UC Santa Barbara History Professor's Book Elucidates, Celebrates ‘Visioneers' May 14th, 2013
Conceptual Nanomedical Lipofuscin Removal Strategy April 29th, 2013
The Global Desalination Market 2013-2023 April 24th, 2013
Nanomedicine
Nanotechnology could help fight diabetes: Injectable nanogel can monitor blood-sugar levels and secrete insulin when needed May 16th, 2013
Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013
Pitt Chemists Demonstrate Nanoscale Alloys So Bright They Could Have Potential Medical Applications: “Think about a particle that will not only help researchers detect cancer sooner but be used to treat the tumor, too.” May 15th, 2013
Using clay to grow bone: Researchers use synthetic silicate to stimulate stem cells into bone cells May 15th, 2013
Announcements
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
NanoInk, Inc. Assets To Be Sold May 18th, 2013
NIA Public Briefing: Nanotechnology and the Council of Europe May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013